Orbimed Advisors LLC Vertex Pharmaceuticals Inc Transaction History

Orbimed Advisors LLC

$4.24 Billion
Q3 2024

A detailed history of Orbimed Advisors LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Orbimed Advisors LLC holds 151,000 shares of VRTX stock, worth $68.1 Million. This represents 1.66% of its overall portfolio holdings.

Number of Shares

151,000

Previous 151,000 -0.0%

Holding current value

$68.1 Million

Previous $70.8 Million 0.78%

% of portfolio

1.66%

Previous 1.71%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $11.1 Million - $13.7 Million	28,300 Added 23.06%	151,000 $70.8 Million
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $21.4 Million - $23.4 Million	-52,500 Reduced 29.97%	122,700 $51.3 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $3.36 Million - $4.02 Million	9,800 Added 5.93%	175,200 $71.3 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $3.84 Million - $4.29 Million	-12,200 Reduced 6.87%	165,400 $58.2 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $26.6 Million - $30.3 Million	-93,900 Reduced 34.59%	177,600 $56 Million
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $29.1 Million - $32.7 Million	-101,700 Reduced 27.25%	271,500 $78.4 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $3.83 Million - $4.28 Million	-14,000 Reduced 3.62%	373,200 $108 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $3.05 Million - $3.8 Million	-13,000 Reduced 3.25%	387,200 $109 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $57.1 Million - $67.3 Million	-257,900 Reduced 39.19%	400,200 $104 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $38.8 Million - $49 Million	-219,300 Reduced 24.99%	658,100 $145 Million
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $34.1 Million - $38.2 Million	-188,000 Reduced 17.65%	877,400 $159 Million
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $13.2 Million - $15.6 Million	-70,500 Reduced 6.21%	1,065,400 $215 Million
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $62.5 Million - $72.8 Million	301,800 Added 36.18%	1,135,900 $244 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $34.8 Million - $46.4 Million	168,000 Added 25.22%	834,100 $197 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $16.1 Million - $21.1 Million	-71,300 Reduced 9.67%	666,100 $193 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $9.13 Million - $11.3 Million	-45,700 Reduced 5.84%	737,400 $175 Million
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $10.6 Million - $14.2 Million	-63,300 Reduced 7.48%	783,100 $171 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $21.1 Million - $23.7 Million	-126,900 Reduced 13.04%	846,400 $143 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $2.96 Million - $3.43 Million	18,000 Added 1.88%	973,300 $178 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $29.1 Million - $34.6 Million	-177,900 Reduced 15.7%	955,300 $176 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $71 Million - $89.8 Million	-467,300 Reduced 29.2%	1,133,200 $188 Million
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $32.2 Million - $37 Million	-192,100 Reduced 10.72%	1,600,500 $308 Million
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $9.03 Million - $10.5 Million	-62,000 Reduced 3.34%	1,792,600 $305 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $17.2 Million - $20.1 Million	113,300 Added 6.51%	1,854,600 $302 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $45.7 Million - $51.8 Million	-333,002 Reduced 16.05%	1,741,300 $261 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $307 Million - $337 Million	2,074,302	2,074,302 $315 Million

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.

Account

Orbimed Advisors LLC Vertex Pharmaceuticals Inc Transaction History